Systemic mastocytosis requires a carefully structured initial management approach. The protocol is evidence-based and accounts for the patient's individual risk profile, guiding clinicians from initial assessment through to the appropriate first-line intervention.

Initial Management Approach

First-line management in systemic mastocytosis centres on an observational strategy supported by specific preventive measures aimed at reducing mast cell activation. The approach is not uniform — additional preparedness steps apply to patients who meet certain risk criteria. The complete protocol specifies which measures apply, when they are indicated, and what further options exist beyond this initial tier.

References

DOI: 10.1002/ajh.26962

Treatment options in SM range from observation alone (supplemented by preventative measures to avoid precipitating MC degranulation), to symptom management (e.g., treating pruritus or diarrhea) (Table 6), to supportive measures (e.g., red blood cell transfusion or osteoporosis treatment), to cytoreductive therapy for MC debulking in the setting of aggressive, advanced, or treatment-refractory disease.
Avoidance of symptom trigger(s) applies to all patients.
Those at risk of anaphylaxis should carry an emergency kit with self-injected epinephrine (EpiPen) (see text).

View source ↗

First-Line Treatment of Systemic Mastocytosis

Initial Management Approach

References